Global Microbiome Market

Microbiome Market Size, Share, Growth Analysis, By Product(Probiotics, Prebiotics, Symbiotics, Others), By Application(Therapeutics, Diagnostics, Nutrition and Dietics, Others), By Distribution Channel(Retail Pharmacies, Online Pharmacies, Supermarkets and Hypermarket), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35J2043 | Region: Global | Published Date: February, 2024
Pages: 224 | Tables: 92 | Figures: 76

Microbiome Market News

  • In September 2022, Seres Therapeutics Inc completed the FDA BLA submission procedure for SER-109 to prevent recurrent C. difficile infection (rCDI). It is a completely novel therapy approach that has the potential to improve the existing standard of care for rCDI.
  • In September 2022, The FDA's Vaccines and Related Biological Products Advisory Committee approved Ferring Pharmaceuticals' RBX2660 investigational microbiota-based live biotherapeutic research for its potential to decrease the recurrence of C. difficile infection (CDI) after antibiotic therapy.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Microbiome Market size was valued at USD 573.42 billion in 2019 and is poised to grow from USD 743.21 billion in 2023 to USD 5918.61 billion by 2031, growing at a CAGR of 29.61% in the forecast period (2024-2031).

The market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies in order to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D in order to supply industries with the most efficient and cost-effective solutions. 'Second Genome Inc.', 'Viome Inc.', 'uBiome Inc.', 'Enterome SA', 'Seres Therapeutics Inc.', 'Rebiotix Inc.', 'Vedanta Biosciences Inc.', 'Microbiome Insights Inc.', 'Microbiome Therapeutics LLC', 'Finch Therapeutics Group Inc.', 'BiomX Inc.', 'Synlogic Inc.', 'Immuron Ltd.', 'Axial Biotherapeutics Inc.', 'AOBiome LLC', 'Evelo Biosciences Inc.', 'Diversigen Inc.', 'DayTwo Inc.', 'Biomillenia SAS', 'Caelus Health Inc.'

Increasing focus on human microbiome therapeutics development

Increasing collaborations between public-private organizations

North America is expected to account for the lion's share of the global human microbiome market. The region's domination is due to the rising prevalence of lifestyle problems and advances in next-generation sequencing. For example, Illumina Inc., a major player in the United States, claims that the introduction of next-generation sequencing enables various high-profile joint projects, like the Human Microbiome Project and MetaHIT. Using Next Generation Sequencing as a basic tool, these projects have published a wide range of data on the human microbiome.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Microbial Protein Market
Buy Now GET FREE SAMPLE
Microbial Identification Market
Buy Now GET FREE SAMPLE
Microbiome Sequencing Services Market
Buy Now GET FREE SAMPLE
Probiotics Market
Buy Now GET FREE SAMPLE
Prebiotics Market
Buy Now GET FREE SAMPLE
Microbial Control Chemical Market
Buy Now GET FREE SAMPLE
Rapid Microbiology Testing Market
Buy Now GET FREE SAMPLE
Bacteriophage Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Microbiome Market

Report ID: SQMIG35J2043

$5,300
BUY NOW GET FREE SAMPLE